Otherwise, as a crucial targeted therapeutic agent, lenvatinib also induces ferroptosis by suppressing the expression SLC7A11 and GPX4 in HCC; moreover, NRF2-overexpressing HCC cells display resistance to lenvatinib and low lipid ROS levels, suggesting lenvatinib-induced ferroptosis is regulated by NRF2 (Iseda et al., 2022). This evidence concerns the gene GPX4 and hepatocellular carcinoma.